奥锐特子公司获雌二醇片/雌二醇地屈孕酮片复合包装注册批件

Core Viewpoint - Aorite (605116.SH) announced that its wholly-owned subsidiary, Yangzhou Aorite Pharmaceutical Co., Ltd., received a drug registration certificate from the National Medical Products Administration for a combination packaging of estradiol tablets and estradiol/dydrogesterone tablets, which is intended for the treatment of perimenopausal syndrome caused by natural or surgical menopause [1] Group 1 - The newly approved product, branded as "Aoshutong," is classified under the new registration category for chemical drugs, which enhances the company's market competitiveness in this pharmaceutical area [1] - The approval of this product is expected to have a positive impact on the company's operational performance due to its anticipated domestic market launch [1]